Published On: Wed, Oct 19th, 2016

Current Price Targets For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)


Recently stock market analysts have updated their consensus ratings on shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Most recent broker ratings

10/04/2016 – Brean Capital began new coverage on Inovio Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 18 price target on the stock.

08/29/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 17 price target on the stock.

08/11/2016 – Inovio Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Maxim Group.

08/08/2016 – Inovio Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 31 price target on the stock.

07/15/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 13 price target on the stock.

06/21/2016 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Rodman & Renshaw. They now have a USD 17 price target on the stock.

05/18/2015 – Inovio Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 9 price target on the stock.

11/19/2014 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 19 price target on the stock.

11/17/2014 – Inovio Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 18 price target on the stock.

Inovio Pharmaceuticals, Inc. has a 50 day moving average of 9.20 and a 200 day moving average of 9.61. The stock’s market capitalization is 608.24M, it has a 52-week low of 4.50 and a 52-week high of 11.69.

The share price of the company (NASDAQ:INO) was up +1.47% during the last trading session, with a high of 8.35 and the volume of Inovio Pharmaceuticals, Inc. shares traded was 791016.

Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.